ClinicalTrials.gg
CompletedNCT02141347Updated Dec 12, 2018

Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma

A Phase 1 interventional study of Tremelimumab and MEDI4736 in Part A and B: Advanced Solid Malignancies and Part C: Malignant Mesothelioma, sponsored by AstraZeneca. Completed at 11 sites in Japan. Open to participants aged 20 Years to 130 Years. Per ClinicalTrials.gov, last updated 2018-12-12.

Sponsored by AstraZeneca · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
65
Allocation
Non-randomized
Ages
20 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Mesothelioma, Malignant with a site in Japan — 1 open to participants now, 3 under way, 1 of them phase 3. Mesothelioma, Malignant · Japan.

Started
2014
the only one that year
Phase 1
Only one
of the 10
Registered
3rd of 10
by date
Lead sponsor
2 of 10
AstraZeneca

Among the 10 studies in Mesothelioma, Malignant with a site in Japan, this one is the only one that started in 2014, is the only one in phase 1, and was the 3rd registered.

Mesothelioma, Malignant

339 studies on the registry are indexed under Mesothelioma, Malignant; 63 are open to participants now.

Browse Mesothelioma, Malignant studies →

Open to participants now

1 of the 10 studies in Mesothelioma, Malignant with a site in Japan is open now. Recruiting first, the newest first:

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 54 Mesothelioma, Malignant studies recruiting now, 42 (78%) set no upper age limit and 5 (9%) stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.

This study: 20 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Mesothelioma, Malignant with a site in Japan, or all of them as a file.
02

Study summary

A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, PK and Preliminary Anti-tumor Activity when given as a monotherapy of Tremelimumab or Tremelimumab in combination with MEDI4736 in Japanese Patients with Advanced Solid Malignancies, and when given as a monotherapy of tremelimumab in Second- or Third-line Treatment of Japanese Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma

Read the detailed description

Primary objectives Part A: To investigate the safety and tolerability of tremelimumab when given to Japanese patients with advanced solid malignancies and define the dose(s) for further clinical evaluation.

Part B: To investigate the safety and tolerability of tremelimumab in combination with MEDI4736 when given to Japanese patients with advanced solid malignancies and to define the dose(s) for further clinical evaluation.

Part C: To investigate the safety and tolerability of tremelimumab when given to Japanese patients with unresectable pleural or peritoneal malignant mesothelioma.

03

Conditions studied

  • Part A and B: Advanced Solid Malignancies
  • Part C: Malignant Mesothelioma
04

Who can participate

Ages eligible
20 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Part A and B:

Inclusion Criteria: 1. Japanese aged at least 20 years old at a time of enrollment. 2. Histological or cytological confirmation of a solid malignant tumor excluding lymphoma that is to standard therapies or for which no standard therapies exist. 3. Performance Status 0-1 with no deterioration over the previous 2 weeks and minimum of 12 weeks at a time of randomization. 4. At least one lesion (measurable and/or non-measurable) that can be accurately assessed at baseline by CT, MRI or plain X-ray and is suitable for repeated assessment. 5. Adequate bone marrow, hepatic, and renal function 6. Willingness to provide consent for archival samples if available.

Exclusion Criteria: 1. Received any prior treatment with monoclonal antibody against Programmed death 1 (PD1), Programmed death ligand 1 () and CTLA-4 (eg, ipilimumab) 2. The last dose of prior chemotherapy or radiation therapy was received less than 2 weeks prior to randomization 3 Currently receiving systemic or other medications or has a medical condition that requires the chronic use of corticosteroids. 4. Receipt of within 30 days of starting tremelimumab treatment 5. Active, untreated central nervous system (CNS) (subjects with who are identified at screening 6. History of other unless the subject has been disease-free for at least 3 years. 7. Any unresolved chronic toxicity grade ≥2 from previous anticancer therapy at the time of randomization, 8. Major surgical procedure within 30 days of starting

Part C:

Inclusion Criteria: 1. Japanese aged 20 and over at the time of consent 2. and/or cytologically confirmed pleural or peritoneal malignant mesothelioma 3. Disease not amenable to curative surgery 4. ECOG Performance status 0-1 5. Progressed after previous receipt of 1-2 prior systemic treatments for advanced disease that included a pemetrexed (or anti-folate)-based regimen in combination with platinum agent. 6. , defined as at least 1 lesion (measurable) that can be accurately assessed at baseline by computed tomography CT or MRI and is suitable for repeated assessment. 7. Adequate bone marrow, hepatic, and renal function Exclusion Criteria: 1. Subjects who failed more than 2 prior systemic treatment regimens for advanced malignant mesothelioma 2. Received any prior mAb against CTLA-4, PD1 or PD-L1 3. History of chronic inflammatory or disease. 4. Symptomatic, untreated CNS metastasis. 5. Any serious uncontrolled medical disorder or active infection that would impair the subject's ability to receive product. 6. History of other malignancy. 7. History of diverticulitis, inflammatory bowel disease, sarcoidosis syndrome 8. Currently receiving systemic corticosteroids or other immunosuppressive medications. 9. Vaccinated with live attenuated vaccines within 30 days prior to starting tremelimumab treatment 10. Not recovered from all toxicities associated with prior cancer treatment to acceptable baseline status, or a NCI CTCAE ver.3.0 Grade of 0 or 1

Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Masking
None (open label)
Enrollment
65 participants (actual)

Study arms

  • Other
    Part A

    Dose escalation of tremelimumab mono therapy for advanced solid malignancies

    Drug: Tremelimumab

  • Other
    Part B

    Combination therapy of tremelimumab and MEDI4736 for advanced solid malignancies

    Drug: Tremelimumab · Drug: MEDI4736

  • Other
    Part C

    Fixed dose of tremelimumab for malignant mesothelioma

    Drug: Tremelimumab

Interventions

  • Tremelimumab administered intravenously

  • MEDI4736 administered intravenously.

06

What researchers measure

Primary outcomes

  1. Adverse event

    To investigate the safety and tolerability of tremelimumab and/ or MEDI4736 when given to Japanese patients

    Time frame: From time of informed consent to 90 days after the last dose

07

Study locations

11 sites
  • Research Site
    Bunkyo-ku, 113-8431, Japan
  • Research Site
    Chuo-ku, 104-0045, Japan
  • Research Site
    Hiroshima-shi, 734-8551, Japan
  • Research Site
    Nagoya-shi, 464-8681, Japan
  • Research Site
    Nishinomiya-shi, 663-8501, Japan
  • Research Site
    Okayama-shi, 702-8055, Japan
  • Research Site
    Osaka-shi, 541-8567, Japan
  • Research Site
    Sapporo-shi, 003-0804, Japan
  • Research Site
    Sunto-gun, 411-8777, Japan
  • Research Site
    Ube-shi, 755-0241, Japan
  • Research Site
    Yokohama-shi, 236-0051, Japan
08

References and documents

Publications

  • Fujiwara Y, Takahashi Y, Okada M, Kishimoto T, Kondo S, Fujikawa K, Hayama M, Sugeno M, Ueda S, Komuro K, Lanasa M, Nakano T. Phase I Study of Tremelimumab Monotherapy or in Combination With Durvalumab in Japanese Patients With Advanced Solid Tumors or Malignant Mesothelioma. Oncologist. 2022 Sep 2;27(9):e703-e722. doi: 10.1093/oncolo/oyac099. PubMed 35671201 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2014 to primary completion in Jan 2017, 32 months.

Of 40 phase 1 interventional studies under Mesothelioma, Malignant, half reached primary completion within 63 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 89. This study's 32 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2014
First posted
May 19, 2014
StartActual
May 22, 2014
Primary completionActual
Jan 27, 2017
CompletionActual
Jan 27, 2017
Last update
Dec 12, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02141347
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
May 19, 2014
Start date
May 22, 2014
Primary completion
Jan 27, 2017
Completion
Jan 27, 2017
Last update
Dec 12, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tremelimumab · Durvalumab

Start the discussion